Home > Press > Nanostart holding Nanosys cooperates with Harvard
Abstract:
* Farreaching agreements signed
* Nanosys complements core business focus with out-licensing program
* Revolutionary technology for biosensor and non-volatile memory
Nanosys Inc. announced that it has signed two agreements with Harvard University to combine their extensive intellectual property (IP) assets to facilitate out-licensing in two areas: nanowire-based biosensors and nanowire-based non-volatile memories. The IP is available for out-licensing to any interested third parties. The technologies being made available originate from the laboratory of Dr. Charles Lieber (Mark Hymen Professor of Chemistry at Harvard University), as well as many other nanotech researchers at Nanosys and other universities associated with Nanosys. The IP on offer includes Nanosys' extensive portfolio covering all aspects of nanowire production, functionalization, material interface technologies, fabrication technologies, basic devices using nanostructures, applications and architectures, and Harvard's portfolio of nanowire-based biosensor and non-volatile memory related IP.
"The agreements between Nanosys and Harvard reflect an innovative strategy to facilitate the development of two novel disruptive technologies," said Isaac T. Kohlberg, Harvard University's Senior Associate Provost and Chief Technology Development Officer. "We're delighted to be working in concert with Nanosys, a recognized leader in the nanowire space, to identify companies interested in acquiring rights to our innovative nanowire technologies for next-generation biosensors and non-volatile memory."
Andrew Filler, General Counsel and Vice-President of Intellectual Property at Nanosys, commented: "As companies are now realizing the significant commercial value of nanotechnology to expand upon and open up new markets, our goal is to help these companies address these markets using our intellectual property portfolio." He added "After developing many fundamental technology platforms at Nanosys over the last several years, the company is now focused on commercializing technologies in core business areas including solid state lighting, electronics, energy storage and medical device applications. Our nanotechnology licensing program compliments our core business focus, thereby providing the market with a convenient licensing option to our fundamental patent portfolio in areas that we are not fully exploiting ourselves."
About Nanostart:
Nanostart AG is the world's leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.
####
About Nanosys Inc.
Nanosys, Inc. is a leader in the development of nanotechnology-enabled products utilizing high performance inorganic nanostructures. Nanosys has built one of the broadest technology platforms in the industry with approximately 500 patents and patent applications covering fundamental areas of nanotechnology. Based in Palo Alto, California and privately held, Nanosys collaborates with industry leaders to develop revolutionary high-value, high-performance products for computing, optoelectronics, communications, renewable energy, defense and the life sciences.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.
For more information, please click here
Contacts:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail:
Copyright © Nanosys, Inc.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Memory Technology
Utilizing palladium for addressing contact issues of buried oxide thin film transistors April 5th, 2024
Interdisciplinary: Rice team tackles the future of semiconductors Multiferroics could be the key to ultralow-energy computing October 6th, 2023
Researchers discover materials exhibiting huge magnetoresistance June 9th, 2023
Sensors
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Groundbreaking precision in single-molecule optoelectronics August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||